Received: 2 December 2020
Accepted: 30 March 2021
First Online: 7 April 2021
: US Government Regulation CFR 46.104 (d) (4) (ii) permits the retrospective analysis of de-identified clinical test results, and the use of leftover de-identified sera without patient consent and institutional review board approval. All methods were performed in accordance with the Declaration of Helsinki and CFR 46.104 (d) (4) (ii).
: Not applicable.
: JSS is an employee of IGeneX and stockholder in ID-FISH and IGeneX. HHP is an employee and RR an affiliate of ID-FISH; PB and IC are employees of IGeneX; JSS, SL, HHP and PB are inventors in the US Provisional Patent Application No. 63/149,998 (2021) - Specific antigen sequences for COVID-19 and methods of use. DF and AB have no competing interests.